Latest Articles
Immunotherapy Data “Very Much Practice-Changing” in Endometrial Cancer - Oncology News Central
Immunotherapy Data “Very Much Practice-Changing” in Endometrial Cancer Oncology News Central
Published: March 20, 2024, 7 a.m.
Rucaparib Maintenance Boosts PFS in Metastatic, Recurrent Endometrial Cancer - Medpage Today
Rucaparib Maintenance Boosts PFS in Metastatic, Recurrent Endometrial Cancer Medpage Today
Published: March 19, 2024, 7 a.m.
Studying Endometrial Cancer in Black Women - news.med.miami.edu
Studying Endometrial Cancer in Black Women news.med.miami.edu
Published: March 18, 2024, 7 a.m.
Dr Marth on Frontline Lenvatinib Plus Pembrolizumab in Endometrial Cancer - OncLive
Dr Marth on Frontline Lenvatinib Plus Pembrolizumab in Endometrial Cancer OncLive
Published: March 18, 2024, 7 a.m.
GSK Builds Case for Broader Jemperli Label in Endometrial Cancer with Phase III Data - BioSpace
GSK Builds Case for Broader Jemperli Label in Endometrial Cancer with Phase III Data BioSpace
Published: March 18, 2024, 7 a.m.
AstraZeneca, GSK make case for broad immunotherapy uses in endometrial cancer. But questions remain - FiercePharma
AstraZeneca, GSK make case for broad immunotherapy uses in endometrial cancer. But questions remain FiercePharma
Published: March 18, 2024, 7 a.m.
“Unprecedented OS Benefit” Seen in Advanced, Recurrent Endometrial Cancer - Oncology News Central
“Unprecedented OS Benefit” Seen in Advanced, Recurrent Endometrial Cancer Oncology News Central
Published: March 17, 2024, 7 a.m.
RUBY Part 2 trial results: Potentially practice changing results in advanced/recurrent endometrial cancer - EurekAlert
RUBY Part 2 trial results: Potentially practice changing results in advanced/recurrent endometrial cancer EurekAlert
Published: March 16, 2024, 7 a.m.
Research reveals link between environmental pollutants and endometrial cancer - News-Medical.Net
Research reveals link between environmental pollutants and endometrial cancer News-Medical.Net
Published: March 14, 2024, 7 a.m.
Dostarlimab given NICE go-ahead in first-line combination treatment for endometrial cancer - Hospital Healthcare
Dostarlimab given NICE go-ahead in first-line combination treatment for endometrial cancer Hospital Healthcare
Published: March 14, 2024, 7 a.m.
Link copied to clipboard!